Loading
A phase 1 trial of BBI-940 run by Boundless Bio, Inc., terminated.
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer is a phase 1 interventional study registered as NCT07408089 by Boundless Bio, Inc., with 8 participants enrolled, started 2026-02-25. Conditions recorded: Breast Cancer, Metastatic Breast Cancer and Advanced Breast Cancer. Interventions recorded: BBI-940 and Fulvestrant.
Shares Boundless Bio and the tag pipeline.
Shares Boundless Bio, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/